Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
press releaseinvestorvideoARCHIVE
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of BiomanufacturingNovember 13, 2024
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQ
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQNovember 13, 2024
ARCHIVE: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024November 12, 2024
ARCHIVE: Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Pricing of $15 Million Initial Public OfferingNovember 11, 2024
ARCHIVE: With NREL's Help, GCxN Company Readies for Initial Public Offering
press clippingsARCHIVE
ARCHIVE: With NREL's Help, GCxN Company Readies for Initial Public OfferingSeptember 30, 2024
NREL
biofuelinvestorscienceARCHIVE
ARCHIVE: NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chatAugust 2, 2024
ARCHIVE: Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou Basenese
investorvideoARCHIVE
ARCHIVE: Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou BaseneseJuly 30, 2024
ARCHIVE: Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou Basenese
investorvideoARCHIVE
ARCHIVE: Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou BaseneseJuly 17, 2024
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
press releaseinvestorARCHIVE
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne TechnologiesJuly 11, 2024
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investors
investorvideoARCHIVE
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investorsJune 18, 2024
Previous page
Page 9 of 11
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark